Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16B* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.3098079APPARATUS AND METHOD FOR POINT-OF-CARE, RAPID, FIELD-DEPLOYABLE DIAGNOSTIC TESTING OF COVID-19, VIRUSES, ANTIBODIES AND MARKERS - AUTOLAB 20
CA 19.03.2021
Int.Class G01N 21/64
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63optically excited
64Fluorescence; Phosphorescence
Appl.No 3098079 Applicant AUTONOMOUS MEDICAL DEVICES, INC. Inventor

An automated system communicated to a remote server for diagnostically field
testing a
sample taken from a patient using an automated portable handheld instrument to

determine the presence of Covid-19 and/or antibodies thereto includes
microfluidic
circuits defined in a rotatable disk for performing a bioassay using a
microarray to
generate an electrical signal indicative of a bioassay measurement; the
microarray
operationally positioned in the microfluidic circuit; one or more lasers; one
or more
positionable valves in the microfluidic circuit; and a backbone unit for
rotating the disk
according to a protocol to perform the bioassay, for controlling the lasers to
selectively
open the positionable valves in the microfluidic disk, for operating the
microarray to
generate a digital image as a bioassay measurement; for communicating the
bioassay
measurement to the remote server, and for associating the performed bioassay
and its
corresponding bioassay measurement to the patient.

2.3093147AN AUTOMATED, CLOUD-BASED, POINT-OF-CARE (POC) PATHOGEN AND ANTIBODY ARRAY DETECTION SYSTEM AND METHOD
CA 17.11.2020
Int.Class G01N 35/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
35Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/-G01N33/148; Handling materials therefor
Appl.No 3093147 Applicant AUTONOMOUS MEDICAL DEVICES, INC. Inventor

An automated method of assaying a viral and antibody analyte in a sample in a
portable, handheld microfluidic reader having a SAW detector with a minimal
mass
sensitivity limitation includes the steps of automatically performing the
assay with the
SAW detector with enhanced sensitivity, but also includes the steps of
automatically
disposing a second portion of the sample on a microarray, selectively
automatically
probing the second portion of the sample for antibodies corresponding to the
at least one
selected virus using the microarray, and automatically reading the microarray
using a
fluorescent camera to identify antibodies in the second portion of the sample.

3.20210102197DESIGNING SENSITIVE, SPECIFIC, AND OPTIMALLY ACTIVE BINDING MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS
US 08.04.2021
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No 17065504 Applicant THE BROAD INSTITUTE, INC. Inventor Pardis SABETI

The invention provides for methods for designing sensitive, specific, and optimally active binding molecules. Systems, methods and compositions utilizing the designed molecules in diagnostics and therapeutics are also provided.

4.WO/2020/198865OLIGOPEPTIDES FOR QUANTITATIVE VIRAL PROTEOMIC ANALYSIS METHODS AND USES
WO 08.10.2020
Int.Class C07K 14/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
18Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
Appl.No PCT/CA2020/050431 Applicant THE UNIVERSITY OF BRITISH COLUMBIA Inventor JEAN, François
Provided are purified oligopeptides, labelled oligopeptides, and stable isotope labelled oligopeptides, methods for their use in determining the maturation status of the flaviruses or coronaviruses in a human biological sample. The purified oligopeptides, labelled oligopeptides, and stable isotope labelled oligopeptides may also be used to measure the level of the flavirus protein or coronavirus protein in a human biological sample. Methods are also provided for treating a subject based on the maturation status of the flaviruses or the coronaviruses in the subject's biological sample and/or based on the level of the flavirus or coronavirus protein in the subject's biological sample.
5.20210012869Systems and Methods for Real-Time Health Certification Using Point-of-Care Data
US 14.01.2021
Int.Class G16H 15/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
15ICT specially adapted for medical reports, e.g. generation or transmission thereof
Appl.No 17037563 Applicant Biosafety Diagnostics, Inc. Inventor Michael Kotlarz

A health pass system for COVID-19 is provided. The system includes a database including information on a plurality of individuals. The database is configured to receive point-of-care data relating to the plurality of individuals, the point-of-care data including at least one medical test result for COVID-19 antibodies for at least one of the plurality of individuals. The system includes a processing device configured to analyze the point-of-care data and generate a report. The system includes means for transmitting the report to a mobile electronic device of at least one of the plurality of individuals. The system includes means for displaying the report with a user interface of the mobile electronic device in the form of a real-time health certification.

6.10968493Rapid diagnostic test using colorimetric LAMP
US 06.04.2021
Int.Class G01N 21/78
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
77by observing the effect on a chemical indicator
78producing a change of colour
Appl.No 16938575 Applicant New England Biolabs, Inc. Inventor Nathan Tanner

Kits and methods are provided for performing multiplex LAMP reactions. These kits and methods are directed to specific and sensitive methods of target nucleic acid detection and more specifically pathogen diagnostics such as detection of Coronavirus. The kits and methods utilize a plurality of sets of oligonucleotide primers for targeting different template sequences in a single nucleic acid target. The kits and methods also include guanidium salts that enhance the sensitivity of the assay.

7.20180265935Virome capture sequencing platform, methods of designing and constructing and methods of using
US 20.09.2018
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No 15759937 Applicant The Trustees of Columbia University in the City of New York Inventor Walter Ian Lipkin

The present invention provides novel methods, systems, tools, and kits for the simultaneous detection, identification and/or characterization of all viruses known or suspected to infect vertebrates. The methods, systems, tools, and kits described herein are based upon the virome capture sequencing platform (“VirCapSeq-VERT”), a novel platform developed by the inventors. The invention also provides methods and kits for designing and constructing of the virome capture sequencing platform.

8.WO/2021/026025METHOD OF TESTING FOR SPECIFIC ORGANISMS IN AN INDIVIDUAL
WO 11.02.2021
Int.Class C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
Appl.No PCT/US2020/044605 Applicant HAZAN, Sabine Inventor HAZAN, Sabine
A method of testing for specific organisms in an individual comprising the steps of: a) screening the individual; b) acquiring a stool sample from the individual; c) processing the stool sample to obtain the individual's microbiome; d) sequencing the microbiome of the individual; and e) analyzing the microbiome of the individual to determine whether one or more specific organisms are present in the individual, whereby a health condition of the individual is determined. The step of processing can comprise the sub-steps of: i) extracting DNA from the stool sample, which comprises adding the stool sample to a bead beating tube, achieving cell lysis, capturing the DNA on a silica membrane in a spin-column, and washing and eluting the DNA from the membrane; and ii) purifying the extracted DNA. A method of determining whether an individual has a health condition comprising the same steps. A stool sample collection kit.
9.111334868Construction method of novel coronavirus whole-genome high-throughput sequencing library, and kit for library construction
CN 26.06.2020
Int.Class C40B 50/08
CCHEMISTRY; METALLURGY
40COMBINATORIAL TECHNOLOGY
BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
50Methods of creating libraries, e.g. combinatorial synthesis
08Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
Appl.No 202010225821.0 Applicant FUZHOU FURUI MEDICAL INSPECTION LABORATORY CO., LTD. Inventor WANG YANG
The invention provides a construction method of a novel coronavirus whole-genome high-throughput sequencing library, and a kit for library construction. The method comprises the following steps: 1) carrying out reverse transcription on virus RNA; (2) carrying out a first round of PCR reaction by utilizing multiple amplification primers of an anchoring part Illumina linker sequence; and 3) carryingout a second round of PCR reaction by using a labeled Illumina library amplification primer, and purifying the amplification product to obtain the high-throughput sequencing library. The anchoring multiplex amplification primer combination provided by the invention is utilized, so the efficient targeted enrichment can be performed on the genome of the novel coronavirus COVID-19, the influence that an existing method is low in targeting, low in experimental timeliness and prone to being brought into host background pollution is overcome, COVID-19 virus whole genome sequencing can be completedwithin a short time with the small sequencing data volume and cost, so differential diagnosis and virus mutation identification of the COVID-19 virus are achieved.
10.202111002831“DISCOVEY OF IMATINIB A DRUG FOR TREATING CORONAVIRIDAE FAMILY OF VIRUS”
IN 12.02.2021
Int.Class G16C /
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
Appl.No 202111002831 Applicant Dr. Vishal M. Balaramnavar Inventor Dr. Vishal M. Balaramnavar
A method (300) for identifying a binding site of an Imatinib drug, the method comprising:developing pharmacophore models to extract features from the Imatinib drug;validating the developed pharmacophore models by comparing with pre-defined models of existing coronavirus drugs;performing a ligand-based virtual screening (first virtual screening) of a database of drugs with the validated pharmacophore models; performing a structure-based virtual screening (second virtual screening) of the validated pharmacophore models by structural docking of a target protein into the validated pharmacophore models; assigning a score to each pharmacophore model of the Imatinib drugin order to identify the validated pharmacophore models with a high binding affinity and efficiency; and comparing the score obtained from the ligand-based virtual screening (first virtual screening) and the structure-based virtual screening (second virtual screening) for classifying the scored pharmacophore models based on the target protein binding affinity and efficiency for the coronaviridae family of virus.